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Summary 
The immune  response against  lymphocytic choriomeningitis  virus (LCMV)  was studied in a 
mutant  mouse strain  that  does not possess CD8 § T  lymphocytes.  Virus-specific cytotoxic T 
cell activity was generated in spleens of wild-type mice in an acute LCMV infection but was 
not measurable in mutant mice. Injection of replicating LCMV into footpads of wild-type mice 
induced  a  CD8 +  T  cell-mediated  swelling  that  peaked  on  day 8,  followed by a  CD4 +  T 
cell-mediated swelling that peaked on day 11, whereas mutant mice exhibited only the CD4 + 
T cell-mediated swelling. After intracerebral inoculation with LCMV-Armstrong,  all wild-type 
mice  died  of classical  CD8 §  T  cell-dependent  choriomeningitis  in  8-10 days.  Mutant  mice 
showed  symptoms of general  malaise but  most  of them  survived.  Mutant  mice depleted  of 
CD4 § T  cells by monoclonal antibody treatment  showed no clinical  signs of sickness.  On day 
9 after intravenous infection with LCMV-WE, virus was detected at high titers in spleens  and 
livers  of mutant  mice  but  not  in  those  of wild-type  mice.  On  day  70  after  injection  of 
LCMV-WE into footpads, virus was not detected in wild-type mice and in one of the three mutant 
mice tested,  but was still measurable in kidneys of the other two mutant  mice. These results 
confirm  in  a new animal  model that  CD8 §  T  cell-mediated  immunity  is crucial  in  LCMV 
clearance and in the immunopathological disease during LCMV infection. In addition, our results 
demonstrated  a  less  severe  form  of choriomeningitis  mediated  by CD4 +  T  cells  and  slow 
clearance of LCMV by alternative  pathways  independent  of CD8 + T  cells. 
C 
D8  T  cells play an essential role in the immune  re- 
sponse in mice against lymphocytic choriomeningitis 
virus (LCMV), 1 whereas antibodies of CD4 + T cells do not 
seem to be crucially involved (1-4). A virus-specific cytotoxic 
activity  mediated  by CD8*  T  cells  is  generated  in  mice 
7-9 d  after  an  acute  LCMV  infection  (5).  CD8 + T  cells 
cause a swelling reaction 6-8 d after injection of replicating 
LCMV into footpads, whereas CD4 *  T  cells  are involved 
in the later phase of the swelling (6, 7). Intracerebral injec- 
tion of LCMV into immunocompetent  mice causes-a fatal 
choriomeningitis that has been demonstrated to be mediated 
by CTL  (8,  9).  The respective roles of CD8 + and CD4 § 
T  cells against LCMV infection have so far been studied in 
adoptive transfer experiments (2-4) and in vivo depletion ex- 
periments with mAbs against CD8 and CD4 (10-12).  We 
have now generated a mutant mouse without CD8 expres- 
1 Abbreviation used in  this paper: LCMV, lymphocytic  choriomeningitis 
virus. 
sion by disrupting the Lyt-2 gene, which encodes one subunit 
of the CD8 heterodimer,  with the technology of homolo- 
gous recombination in embryonic stem cells (13). In this mouse 
strain,  it has not been possible to demonstrate the presence 
of class  I MHC-restricted cytotoxic T  cells.  For the study 
of the consequences of the  anti-LCMV  immune  response 
without CD8 + T  cells,  this new mouse model has several 
advantages compared to in vivo depletion experiments with 
mAbs.  The mutant  mice are devoid of CD8 § T  cells,  and 
possible problems arising from antibody treatment  such as 
incomplete depletion or stimulation instead of depletion of 
CD8 + T  cells  can be excluded. 
Evaluation of the immune response against LCMV in these 
CD8-defective mice confirms the key role of CD8 § T  cells 
in antiviral protection and immunopathology.  Our results 
ailso reveal  a  CD4 +  T  cell-dependent  immunopathology 
~ter intracerebral  infection with LCMV, and the clearance 
of  LCMV  through  mechanisms  independent  of  CD8 § 
T  cells. 
1425  J.  Exp. Med.￿9  The Rockefeller University Press ￿9 0022-1007/91/12/1425/05  $2.00 
Volume 174  December  1991  1425-1429 Materials  and  Methods 
Mice and Viruses.  The mutant mouse strain without CD8 ex- 
pression was generated using the embryonic stem cell technology 
as described  previously (13).  These mice were H-2  b.  C57BL/6 
(H-2  b) mice were obtained from the breeding colony of the ln- 
stitut fur Zuchthygiene (Tierspital Zurich, Switzerland). All mice 
were between 8 and  16 wk of age. 
LCMV, strain WE (1) and strain Armstrong (2), were obtained 
from Dr. F. Lehmann-Grube (Hamburg, FRG) and Dr. M.B.A. 
Oldstone (La Jolla, CA), respectively. Production and titration of 
virus were performed on mouse L cells as described in detail previ- 
ously (14). Titers of virus in infected organs were presented as PFU 
per gram of tissue. 
Cytotoxicity Assay.  9 d after intravenous infection with LCMV- 
WE (200 PFU/mouse), spleen cells were assayed for LCMV-specific 
cytotoxicity in a standard  51Cr release assay as described  in detail 
elsewhere (15). The fibrosarcoma cell line MC57G (H-2  b) infected 
with LCMV-WE  was used as target cells. YAC cells, which are 
sensitive to NK cell activity, and MC57G cells infected with vac- 
cinia virus were used as control target cells for LCMV specificity. 
The assay was performed in duplicates  with 4 h of incubation at 
37~  and specific lysis was  calculated  as described  (9,  12). 
Swelling Reaction of the Footpad and Assessment of ChoHomenin- 
girls.  Swelling of footpads was measured daily with a spring-loaded 
caliper (1, 6, 7, 12) after 30 #1 of LCMV-WE  (500 PFU/footpad) 
were injected  subcutaneously into  the hind footpads.  After in- 
tracerebral  injection  of 30 kd  of LCMV-Armstrong  (100 PFU/ 
mouse), mice were monitored daily for lethality,  clinical signs of 
choriomeningitis (2, 4, 8), and reduction of body weight. Change 
of body weight was calculated as: (body weight after infection - 
body weight before infection)/(body weight before infection). 
In Vivo Depletion of CIM § or CD8*  Cells.  mAbs produced by 
hybridoma cell lines YTS 169.4 and YTS 191.1, which are specific 
for mouse CD8 (Lyt-2) and CD4 (L3T4), respectively,  were ob- 
tained from Dr. H. Waldmann (Cambridge, UK), and were pre- 
pared as described (10). CD4"  or CD8 § T cells were depleted by 
intravenous injection with 1 mg of the respective antibody 3 and 
1 d before 1 LCMV infection, as described  (10). 
Serothera~  with  Polydonal Anti-IFN-3,  and anti-TNF-ot.  The 
production of sheep antisera  against  IFN-3,  and TNF-ot was de- 
scribed in detail elsewhere  (16, 17). Daily, mice were injected  in- 
traperitoneally with 3  x  10  4 neutralizing units of anti-IFN-% 
anti-TNF-c~, or normal sheep serum, from day 5 after intracerebral 
I.CMV infection. 
Results and Discus,  ion 
Antiviral  Cytotoxic  Activity  during  Acute  LCMV  Infec- 
tion.  Antiviral cytotoxichy activity of spleen cells was as- 
sayed for 9 ,t after intravenous injection of LCMV-WE into 
wild-type mice and mice homozygous and heterozygous for 
the disrupted Lyt-2 gene. Wild-type mice and heterozygous 
mutant  mice  showed  similar  cytotoxic  activities  towards 
LCMV-WE-infected MC57G cells, whereas nonspecific lysis 
of YAC cells and vaccinia virus-infected MC57G cells was 
minimal  (Fig.  1).  Specific cytotoxicity was not detected in 
homozygous mutant mice, but elevated levels of nonspecific 
lysis of YAC cells and vaccinia virus-infected MC57G cells 
were observed. 
Primary Local Swelling Reaction after Intrafootpad Infection with 
LCMV.  Subcutaneous  inoculation  of  LCMV-WE  into 
footpads of mice has been demonstrated  to induce a virus- 
specific swelling reaction (6, 7, 18-20). Wild-type mice and 
heterozygous mutant mice exhibited an initial major swelling 
that peaked on day 8, followed by a later minor swelling phase 
that  started at around day 10,  and then slowly declined in 
inflammation (Fig. 2). The initial swelling has been shown 
to be mediated by CD8 § T  cells, whereas the later swelling 
was mediated by CD4 + T  cells (7,  19,  20).  The CD4+  T 
cell-mediated swelling shown in mutant mice confirms that 
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Figure 1.  Anti-LCMV cytotoxic T 
cell activities  in an acute I.CMV-WE in- 
fection. Wild-type  mice (+/+)  and 
mice heterozygous  (+/-) and homozy- 
gous ( -/- ) for the disrupted Lyt-2  gene 
were  intravenously  injected  with 
LCMV:WE (500 PFU/mouse). Effector 
cells were from spleens of mice (H-2  b) 
on day 9 after infection are as described 
in Materials and Methods. Target cells 
were (A) MC57G cells either infected 
with LCMV-WE or vaccinia virus, and 
(B) YAC cells as control for NK cell ac- 
tivity. 
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Figure 2.  Footpad  swelling  reaction in mice after local infection  with 
LCMV-WE. Swelling  of  footpads  is expressed  as folds  of  footpad  thickness 
compared to that before  inoculation.  Data points represent means  of six 
individual measurements from both hind feet of three mice. 
CD4 § T  cells can mediate local inflammation independent 
of CD8 + T cells after subcutaneous injection with LCMV. 
Development of Choriomeningitis after Intracerebral Infection 
with LCMV.  Intracerebral inoculation with LCMV usually 
leads to fatal choriomeningitis that is not the result of a di- 
rect cytoplasmic effect of the virus but is caused by antiviral 
CD8 + T  cells (8,  9).  After intracerebral infection of mice 
with LCMV Armstrong (100 PFU/mouse), all wild-type mice 
and heterozygous mutant mice showed severe neurological 
impairment starting on day 6 after inoculation and had died 
with characteristic convulsions by day 10 (Fig.  3 A).  One 
out of four homozygous mutant mice died on day 10, the 
others survived but showed symptoms of general malaise and 
reduction of body weight. When homozygous mutant mice 
were treated with mAb to deplete CD4 + T  cells before in- 
tracerebral LCMV infection, they showed no signs of clinical 
sickness  or body weight reduction, whereas mutant mice 
without antibody treatment were sick and lost 22% of their 
body weight, but they all survived (Fig. 3 B). Similar to the 
results shown in mutant mice, C57BL/6 mice (four mice 
tested) depleted of CD8 + T  cells by treatment with mAbs 
before intracerebral LCMV infection were temporarily sick 
but  survived,  whereas  no  symptoms  were  observed  in 
C57BL/6 mice depleted of both CD8 + and CD4 + T  cells 
(data not shown). Thus, our results demonstrate that in con- 
trast  to  the fatal choriomeningitis mediated by CD8 +  T 
cells, CD4 + T  cells also mediate a less severe form of cho- 
riomeningitis in response to LCMV intracerebral infection. 
The time course and the severity of choriomeningitis as as- 
sessed by body weight reduction are comparable to the ki- 
netics and the extent of the local footpad swelling reaction. 
This suggests that an acute and severe inflammation of the 
meninges mediated by CD8 + T  cells causes  the death of 
mice, whereas the moderate and slow development of menin- 
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Figure 3.  Choriomeningitis  induced  by intracerebral  injection  of LCMV- 
Armstrong (100 PFU/mouse)  into mice. (A) Survival  of wild-type  mice 
(+/+) and mice  heterozygous  (+/-) and homozygous  (-/-) for the dis- 
rupted Lyt-2  gene on different  days after infection  is shown. Groups of 
four mice  were used. (B) Effect  of anti-CD4 antibody  treatment  on body 
weight reduction in homozygous  mutant mice. Anti-CD4 antibody  (1 
mg/mouse) was injected intravenously  as described in Materials and 
Methods. Data  points represent means  of  body  weight  change  of two mice 
used in each group. 
gitis mediated by CD4 §  T  cells leads  to  general malaise 
with significant body weight reduction but is not fatal. The 
CD4 + T cell-mediated choriomeningitis indicated as body 
weight reduction was not eliminated  by daily administration 
of polyclonal sheep  anti-TNF-ot nor anti-IFN-~ antiserum 
(data not shown). This treatment has been shown to be effec- 
tive in abrogating CD4 + T  cell-mediated clearance of vac- 
cinia virus in meninges (21) and clearance of Listeria in nude 
mice (22).  This suggests that the CD4 + T  cell-dependent 
choriomeningitis in LCMV infection is mediated through 
other mechanisms. 
Clearance of LCMV in CD8-defective  Mic~  LCMV is mea- 
surable in spleens of mice at high titers on day 4-6 after an 
acute infection, but most of the virus is eliminated by day 
7-8, around the time point of maximal cytotoxic T cell re- 
sponse against viral antigen (23,  24).  CD8 + T  cells have 
been shown to be the effector cells of cytotoxicity and are 
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On day 9 after intravenous infection with LCMV-WE, virus 
was detected at high titers in spleens and livers of the mutant 
mice, whereas wild-type mice and the heterozygous mutant 
mice had already cleared the virus to a level below detection 
(Table 1). For mice inoculated with LCMV-WE in footpads, 
virus was detected in blood samples of all three mutant mice 
but  not  in  those  of wild-type  and  heterozygous  mutant 
mice on day  18 after infection.  On day 70 after infection, 
all mice were killed and the organs, including spleen, liver, 
thymus,  kidney,  pancreas,  ovary  or testis,  lung,  and heart, 
were assayed for virus.  Two of the mutant mice still had de- 
tectable virus in kidneys,  but not in the other organs.  One 
mutant mouse and all the wild-type mice had cleared the virus 
below detection levels (Table 1). Mutant mice that survived 
after intracerebral infection with LCMV-Armstrong were posi- 
tive for virus in blood samples on day 18 after infection. How- 
ever, on day 70 after infection, they were all negative in virus 
assays in all the organs mentioned above (data not shown). 
Taken together, these results confirm that CD8 + T cells are 
crucial for clearance of LCMV after an acute infection. How- 
ever, other cells may also be involved in LCMV clearance, 
although they eliminate LCMV at a considerably  slower rate. 
Table  1.  Titers  of LCMV in Infected  Mice 
LCMV-WE 
intravenous infection 
LCMV-WE 
intrafootpad infection 
Mouse  strain  Day 9  Day 9  Day  18  Day 70  Day 70 
(CD8  genotype)  spleen  liver  blood*  blood  kidney 
PFU/g  PFU/g 
/  2.8  x  107  4.2  x  106  +  +  4.0  x  104 
1.4  x  107  3.3  x  105  +  +  1.5  x  105 
2.3  x  10  7  1.7  x  105  +  -  <10  2 
+ / -  <103  <10  2  -  ND*  <105 
<105  <10  2  -  ND  <103 
<10  3  <10  2  -  ND  <103 
+ / +  <103  <10  2  -  ND  <103 
<103  <10  2  -  ND  <103 
<103  <10  2  -  ND  <I0  z 
* Blood sample was regarded as "+ ", positive for the presence of virus, if a swelling reaction developed after injection of 30/~1 of heparinized blood 
into the footpad of unprimed ICR (H-2q) mice. 
* Virus titer not determined. 
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